Hansa Biopharma AB - Company Profile
Powered by 
All the sales intelligence you need on Hansa Biopharma AB in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Hansa Biopharma AB fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Hansa Biopharma AB.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Business Description
Hansa Biopharma AB (Hansa Biopharma) focuses on harnessing its enzyme technology platform and develops novel immunomodulatory enzymes for transplant rejection and treatment and prevention of rare, cancer and severe autoimmune conditions. It develops novel drugs to advance the treatment of rare, severe and life-threatening IgG mediated conditions in transplantation and autoimmunity.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
Hansa Biopharma is actively involved in various R&D initiatives, including ongoing clinical programs and preclinical research. The company is investigating the use of its technology platform as a pre-treatment in gene therapy and developing its next-generation enzyme for repeat dosing. It is exploring opportunities for imlifidase to potentially enable gene therapy treatment in patients with pre-existing neutralizing antibodies against adeno-associated viral vectors. The company has established collaborations with Sarepta, AskBio, and Genethon to assess imlifidase as a pre-treatment in various diseases. Additionally, Hansa Biopharma is advancing its enzyme technology to develop the next generation of IgG-cleaving enzymes with potentially lower immunogenicity, suitable for repeat dosing, under the NiceR program. In FY2024, the company spent SEK367.2 million.
Geographical Segments
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer